Citations

Clear

1432 citation(s) found for "Uk, Nathan".

Volatile Anesthetics: A Comprehensive Review of Pharmacology, Delivery Systems, and Safety Considerations for ICU Practitioners
Kopańczyk, Rafał , Wieruszewski, Patrick M., Yin, Wenyuan, Mulvoy, William P., Theodore, Danny , Gurnani, Payal K. , Szczypta, Robert E., Naslund, Jenna S., Bank, T. Caroline, Rausen, Michelle , Jarzebowski, Mary, Wilder, Markisha, Patel, Ambrish B., Denchev, Krassimir L, Feichtinger, Stuart, Pearl, Ronald G. , Laudański, Krzysztof , Wieruszewski, Patrick M. , Yin, Wenyuan , Smischney, Nathan J. , Bank, Tracy Caroline , Jarzebowski, Mary, Brainard, Jason C. , Denchev, Krassimir

Mayo Clinic

Critical Care Medicine | January 20, 2026 | Volume: 54 | Issue: 4 | Pages: 926-938

10.1097/ccm.0000000000007042 | PMID 41556744 Get It

OBJECTIVE: Volatile anesthetics (VAs) are gaining renewed interest as a sedation strategy in the intensive care, offering an alternative to traditional IV agents. VAs provide several pharmacologic advantages, including rapid onset and offset, minimal systemic metabolism, and favorable recovery profiles. Advances in delivery systems enabled the safe and practical administration of volatile agents in the ICU. Thus, we aimed to describe the pharmacology and safety aspects of inhaled agents as well as the systems designed to deliver VAs in the ICU. DATA SOURCES: Relevant literature was identified through PubMed and MEDLINE databases. STUDY SELECTION: Original research, review articles, commentaries, and guidelines addressing safety, efficacy, and use of VAs in adult ICU patients were included. DATA EXTRACTION: Studies were reviewed by the authors, with key findings summarized and organized by pharmacologic properties, delivery systems, and safety domains. DATA SYNTHESIS: VAs are halogenated hydrocarbons whose mechanism of action is not fully understood. Although the CNS is the primary site of action, the end-tidal concentration of exhaled anesthetic is used to monitor clinical effects such as immobility to a noxious stimulus. Inhaled agents have unique pharmacokinetics, minimal metabolisms, and distinct recovery. The side effect profile is also unique, with malignant hyperthermia being the most feared, yet rare complication. Two systems for inhalational sedation delivery are available internationally, with one currently under evaluation in the United States. The systems are composed of a miniature vaporizer, delivery controller, and a monitor. The systems have distinct safety considerations, such as tidal volume limits. CONCLUSIONS: VAs can be used as sedative agents in the ICU. This article comprehensively reviews the pharmacology of VAs along with their safety profile and describes the structure and function of miniature vaporizers currently available on the world market.
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET -Altered Solid Tumors: Analysis of the RETgistry Global Consortium
Waliany, Sarah , Cooper, Alissa J. , Liu, Stephen V. , Gautschi, O., Rotow, Julia K. , Smith, Katherine E. , Weber, Urs, Lee, Dae Ho , Loong, H., Patel, Jyoti D. , Nagasaka, Misako , Patel, Shetal , Tan, Daniel S. W., Solomon, Benjamin J., Pall, Georg , Riess, Jonathan W. , Sun, Lova , Früh, Martin, Uy, Natalie F., Gadgeel, Shirish, Feng, Jamie, Leighl, Natasha B., Baik, Christina S. , Lai, G., Ou, S. Ignatius, Cheung, Kingsley S.Y., Patil, Tejas, Weiler, Daniela , Yeap, Beow Y., Wirth, Lori J. , Gainor, Justin F., Drilon, Alexander D., Lin, Jessica J., Loong, Herbert H. , Rotow, Julia , Gautschi, Oliver , Smith, Katherine E R , Weber, Urs M , Loong, Herbert H , Pennell, Nathan A , Nagasaka, Misako , Patel, Shetal A , Tan, Daniel S W , Solomon, Benjamin J , Kim, Tae Min , Pall, Georg , Riess, Jonathan W , Sun, Lova , Früh, Martin , Uy, Natalie F , Gadgeel, Shirish , Feng, Jamie , Do, Andrew , Falcon, Christina , Leighl, Natasha B , Baik, Christina S , Lai, Gillianne G Y , Ou, Sai-Hong I , Cheung, Kingsley S Y , Patil, Tejas , Mansfield, Aaron S , Weiler, Daniela , Yeap, Beow Y , Wirth, Lori J , Gainor, Justin F , Drilon, Alexander , Lin, Jessica J , Liu, Stephen V , Früh, Martin , Gadgeel, Shirish M. , Feng, Jamie , Mansfield, Aaron S. , Gainor, Justin F.

Mayo Clinic

Clinical Cancer Research | January 15, 2026 | Volume: 32 | Issue: 6 | Pages: 1157-1168

10.1158/1078-0432.ccr-25-4382 | PMID 41537704 Get It

Abstract Purpose: Rearranged during transfection (RET) alterations are oncogenic drivers across solid tumors. Selective RET inhibitors (SRI) selpercatinib and pralsetinib have transformed outcomes for patients with RET-altered malignancies. Limited knowledge exists on genomic mechanisms of resistance to SRI. Experimental Design: We established “RETgistry,” a global consortium of patients with advanced RET-altered solid tumors who received SRI and underwent postprogression tissue or plasma biopsies assessed by next-generation sequencing. Frequencies of secondary RET resistance mutations and acquired non-RET gene alterations were determined. Progression-free survival (PFS) and time to treatment discontinuation (TTD) on first SRI were estimated with the Kaplan–Meier method. Results: RETgistry included 109 patients with RET-altered advanced solid tumors (lung, n = 94; thyroid, n = 15) who underwent 143 post-SRI progression biopsies (tissue, 91; plasma, 52). The median PFS and TTD were 13.9 months [95% confidence interval (CI), 10.1–16.6] and 17.3 months (95% CI, 14–20.2), respectively. Secondary RET mutations were detected in 20 (14%) biopsies [lung cancer, 15 (12.4%) and thyroid carcinoma, 5 (22.7%)]. Common acquired off-target alterations involved MET (18.2%; amplification, 15%), TP53 (8.2%), APC (7.6%), KRAS (7.1%), KEAP1 (5.9%), and CDKN2A/B (5.3%). MET alterations were enriched in post-SRI versus pre-SRI specimens (full cohort, 17.6% vs. 2.0%, P = 0.022; lung cancer, 19.1% vs. 2.1%, P = 0.022). Conclusions: The prevalence of secondary RET mutations after SRI was low, underscoring a greater role for off-target resistance. Recurrent acquired alterations involving tumor suppressor genes or upstream regulators of MAPK and PI3K pathways were identified, most commonly MET amplification. Continued efforts to characterize SRI resistance biology are critical to guide the development of novel therapeutic strategies.
Network Hypoactivity in ALG13-CDG: Disrupted Developmental Pathways and E/I Imbalance as Early Drivers of Neurological Features in CDG
Shah, Rameen , Budhraja, Rohit, Radenkovic, Silvia , Preston, Graeme , King, Alexia, Sabry, Sahar A. , Bleukx, Charlotte, Shammas, Ibrahim , Chandran, Jisha, Hrstka, Ronald F., Smith, Doughlas, Pandey, Akhilesh , Morava, Eva, Kozicz, T., Morava, Éva , Kozicz, Tamás , Hrstka, Ronald, Smith, Doughlas Y, Pandey, Akhilesh , Morava, Eva , Kozicz, Tamas , Preston, Graeme , Budhraja, Rohit , Sabry, Sahar, Young, Lyndsay E.A. , Byeon, Seul Kee , Staff, Nathan P. , Drake, Richard R. , Sloan, Steven A.

Mayo Clinic

Cells | January 14, 2026 | Volume: 15 | Issue: 2 | Pages: 147

10.3390/cells15020147 | PMID 41597222 Get It

Background: ALG13-CDG is an X-linked N-linked glycosylation disorder caused by pathogenic variants in the glycosyltransferase ALG13, leading to severe neurological manifestations. Despite the clear CNS involvement, the impact of ALG13 dysfunction on human brain glycosylation and neurodevelopment remains unknown. We hypothesize that ALG13-CDG causes brain-specific hypoglycosylation that disrupts neurodevelopmental pathways and contributes directly to cortical network dysfunction. Methods: We generated iPSC-derived human cortical organoids (hCOs) from individuals with ALG13-CDG to define the impact of hypoglycosylation on cortical development and function. Electrophysiological activity was assessed using MEA recordings and integrated with multiomic profiling, including scRNA-seq, proteomics, glycoproteomics, N-glycan imaging, lipidomics, and metabolomics. X-inactivation status was evaluated in both iPSCs and hCOs. Results: ALG13-CDG hCOs showed reduced glycosylation of proteins involved in ECM organization, neuronal migration, lipid metabolism, calcium homeostasis, and neuronal excitability. These pathway disruptions were supported by proteomic and scRNA-seq data and included altered intercellular communication. Trajectory analyses revealed mistimed neuronal maturation with early inhibitory and delayed excitatory development, indicating an E/I imbalance. MEA recordings demonstrated early network hypoactivity with reduced firing rates, immature burst structure, and shortened axonal projections, while transcriptomic and proteomic signatures suggested emerging hyperexcitability. Altered lipid and GlcNAc metabolism, along with skewed X-inactivation, were also observed. Conclusions: Our study reveals that ALG13-CDG is a disorder of brain-specific hypoglycosylation that disrupts key neurodevelopmental pathways and destabilizes cortical network function. Through integrated multiomic and functional analyses, we identify early network hypoactivity, mistimed neuronal maturation, and evolving E/I imbalance that progresses to compensatory hyperexcitability, providing a mechanistic basis for seizure vulnerability. These findings redefine ALG13-CDG as disorders of cortical network instability, offering a new framework for targeted therapeutic intervention.
Imaging Hereditary Cancer Syndromes in the Abdomen and Pelvis
Suman, Garima , Nehra, Avinash , Bohyun, Kim, Nathan, Mark A., Heiken, Jay P. , Kawashima, Akira , Nathan, Mark, Heiken, Jay , Kawashima, Akira

Mayo Clinic

RadioGraphics | January 8, 2026 | Volume: 46 | Issue: 2 | Pages: No page available

10.1148/rg.250106 | PMID 41505282 Get It

Radiologists are uniquely positioned to play a critical role in the detection, surveillance, and characterization of hereditary abdominal cancer syndromes.
Fibroblasts Exposed to Serum Collected After Long-Term Calorie Restriction Have Lower Mitochondrial Respiration
Seow, Lek Wei , Dozier, Stephen , Sun, Nina, Bergstrom, Jaclyn , LeBrasseur, Nathan K. , Molina, Anthony

Mayo Clinic

Innovation in Aging | January 3, 2026 | Volume: 9 | Issue: Supplement_2 | Pages: No page available

10.1093/geroni/igaf122.2543 Get It

Abstract Multiple lines of evidence suggest that calorie restriction may slow biological processes related to aging and extend lifespan. To determine whether calorie restriction affects mitochondrial function, we treated fibroblasts from adult donors with serum samples obtained from participants of the CALERIE (Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy) study. The CALERIE study enrolled healthy, non-obese middle-aged (average 38y.o) participants to examine the effects of long-term calorie restriction. We studied the serum samples of 177 participants (calorie restriction CR = 121, ad libitum AL = 56) who had specimens available at two timepoints (12 and 24 months). We assessed the basal and maximal mitochondrial respiration of fibroblasts treated with dilute serum for 24 hours. Our results show that the baseline basal and maximal mitochondrial respiration of fibroblasts is positively correlated with the adiposity of the serum donor (R = 0.112, P = 0.137; R = 0.183, P = 0.015, respectively). Interestingly, treatment of fibroblasts with serum collected after 12 months of calorie restriction causes a decrease in both basal and maximal mitochondrial respiration (P = 0.1854; P = 0.0623, respectively). Fibroblasts treated with serum collected after 24 months of calorie restriction exhibited a further reduction in both basal and maximal mitochondrial respiration (P = 0.0174; P = 0.0092, respectively). These findings suggest that the serum of individuals on long term calorie restriction diet comprises factors that can reduce oxidative phosphorylation. This reduction in bioenergetic capacity may align with the theory that calorie restriction leads to a cellular energy-conserving state, which could have implications for cellular aging and metabolism.
Lymphoepithelial Carcinoma of the Salivary Gland: A Systematic Review and Single Institution Experience
Gibbs, Hannah M. , Sramek, Michael T. , Hintze, Justin M. , Gibbs, H G , Hintze, Justin , Vasudevan, Srivatsa Surya , Nathan, Cherie-Ann O , Chang, Brent A.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | December 31, 2025 | Volume: 174 | Issue: 2 | Pages: 297-304

10.1002/ohn.70095 | PMID 41474179 Get It

Abstract Objective Lymphoepithelial carcinoma of the salivary gland (LECSG) is a rare malignancy. The purpose of this study is to evaluate the clinical features of LECSG with a focus on the role of Epstein‐Barr virus (EBV). Data Sources PubMed, Embase, Web of Science, institutional pathology Natural Language search tool. Review Methods Retrospective review of patients diagnosed with LECSG at a single institution and a systematic literature review. Full text articles in English were included. Results 285 cases of LECSG identified via literature review and an additional 10 within our institution. Most tumors were in the parotid gland (70.5%). Lymph node metastasis was observed in 28%. Most cases were in Asian or Inuit patients (70.5%). EBV association was positive in 52%, and 87.6% of these were in endemic populations. Treatment primarily involved surgical resection (65.8%), often combined with adjuvant therapy (50.2%). No significant differences in disease‐free survival (DFS) or disease‐specific survival (DSS) were observed by EBV status. Advanced tumor stage was associated with worse DFS ( P < .0001) and worse DSS ( P < .0001). Lymph node metastasis was also associated with reduced DSS ( P = .04). Independent predictors of poorer DFS and DSS included late tumor and endemic region of origin. Conclusion This comprehensive analysis of 295 salivary gland LEC cases provides valuable insights into the clinical behavior, pathological features, and treatment outcomes of this rare malignancy. The study highlights the potential role of EBV in tumor pathogenesis, particularly in endemic populations, and emphasizes the need for further research to establish optimal management strategies.
Senolytic‐Resistant Senescent Cells Have a Distinct SASP Profile and Functional Impact: The Path to Developing Senosensitizers
Tripathi, Utkarsh , Suda, Masayoshi , Kulshreshtha, Vagisha , Piatkowski, Bryan T, Giorgadze, Nino, Inman, Christina L., Gasek, Nathan , Xu, Ming, Johnson, Kurt O. , Pirtskhalava, Tamar , Chaib, Selim , Prata, Larissa P. G. Langhi, Zhu, Yi , Kandhaya‐Pillai, Renuka , Tullius, S., Wyles, Saranya P. , Majji, Rambabu, Tchkonia, Tamar, Kirkland, James L., Inman, Christina, Chaib, Selim , Yalamanchili, Hari Krishna , Zhu, Yi , Suda, Masayoshi , Tripathi, Utkarsh , Piatkowski, Bryan , Palmer, Allyson K. , Prata, Larissa , Rambabu, Majji , Allison, David B. , Tchkonia, Tamar , Kirkland, James L.

Mayo Clinic

Aging Cell | December 30, 2025 | Volume: 25 | Issue: 1 | Pages: No page available

10.1111/acel.70358 | PMID 41462575 Get It

ABSTRACT The senescent cell (SC) fate is linked to aging, multiple disorders and diseases, and physical dysfunction. Senolytics, agents that selectively eliminate 30%–70% of SCs, act by transiently disabling the senescent cell antiapoptotic pathways (SCAPs), which defend those SCs that are proapoptotic and pro‐inflammatory from their own senescence‐associated secretory phenotype (SASP). Consistent with this, a JAK/STAT inhibitor, Ruxolitinib, which attenuates the pro‐inflammatory SASP of senescent human preadipocytes, caused them to become “senolytic‐resistant”. Administering senolytics to obese mice selectively decreased the abundance of the subset of SCs that is pro‐inflammatory. In cell cultures, the 30%–70% of human senescent preadipocytes or human umbilical vein endothelial cells (HUVECs) that are senolytic‐resistant (to Dasatinib or Quercetin, respectively) had increased p16 INK4a , p21 CIP1 , senescence‐associated β‐galactosidase (SAβgal), γH2AX, and proliferative arrest similarly to the total SC population (comprising senolytic‐sensitive plus‐resistant SCs). However, the SASP of senolytic‐resistant SCs entailed less pro‐inflammatory/apoptotic factor production, induced less inflammation in non‐senescent cells, and was equivalent or richer in growth/fibrotic factors. Senolytic‐resistant SCs released less mitochondrial DNA (mtDNA) and more highly expressed the anti‐inflammatory immune evasion signal, glycoprotein non‐melanoma‐B (GPNMB). Transplanting senolytic‐resistant SCs intraperitoneally into younger mice caused less physical dysfunction than transplanting the total SC population. Because Ruxolitinib attenuates SC release of proapoptotic SASP factors, while pathogen‐associated molecular pattern factors (PAMPs) can amplify the release of these factors rapidly (acting as “senosensitizers”), senolytic‐resistant and senolytic‐sensitive SCs appear to be interconvertible.
Senescent Mesenchymal Stromal Cells Differentially Alter Adipogenesis in Adipose Tissue, Skeletal Muscle, and Bone Marrow
Zhang, Xu , Fan, Ting , Tripathi, Utkarsh , Ng, Yan Er, Jiang, Xinyi, Jurk, Diana , Tchkonia, Tamara, Kirkland, James L., Robbins, Paul D., KHOSLA, S, Ng, Yan Er , Doolittle, Madison L. , Jurk, Diana , Zhang, Xu , Fan, Ting, Tripathi, Utkarsh , Passos, João F. , Monroe, David G. , Tchkonia, Tamar , Kirkland, James L. , Robbins, Paul D., Khosla, Sundeep , LeBrasseur, Nathan K.

Mayo Clinic

Obesity | December 24, 2025 | Volume: 34 | Issue: 3 | Pages: 652-661

10.1002/oby.70119 | PMID 41437892 Get It

ABSTRACT Objective Aging alters mesenchymal stromal cell (MSC) function, leading to dysregulated adipogenesis across tissues through biased lineage commitment. Fat redistribution from adipose depots to skeletal muscle and bone marrow is common in aging, but the underlying mechanisms remain unclear. This study investigates how MSC senescence modulates adipogenesis. Methods Primary MSCs were isolated from mouse skeletal muscle (FAPs), adipose tissue (APCs), and bone marrow (BMSCs). Single‐cell RNA sequencing was performed to compare transcriptional profiles among these populations. In vitro adipogenic differentiation and DNA damage–induced senescence assays were conducted, and the effects of autologous conditioned media from senescent MSCs on adipogenesis were assessed. Results Transcriptional analyses revealed that FAPs and APCs share greater similarity with each other than with BMSCs. All MSC types exhibited adipogenic potential and developed a robust senescence‐associated secretory phenotype (SASP) upon senescence induction. Conditioned media from senescent MSCs enhanced adipogenesis in BMSCs but inhibited adipogenesis in FAPs and APCs, revealing tissue‐specific paracrine effects. Conclusions MSC senescence reprograms adipogenic bias in a tissue‐dependent, non–cell autonomous manner, contributing to age‐related fat redistribution among adipose tissue, skeletal muscle, and bone marrow. Understanding these mechanisms may provide new therapeutic approaches for improving tissue composition and function in the context of aging.
The Sixth Annual Symposium of the Midwest Aging Consortium
Sturmlechner, Ines , Ashiqueali, Sarah , Martini, Hélène , Valdivieso, Karla , Franco, Ana Catarina , Guthikonda, Prashanth Kumar, Dosch, Andrew J. , Prieto, Luis I. , Asmussen, Niels C. , Latham, Amanda S. , Redden, James T, Leitschuh, Ethan A , Mashek, Douglas G. , Rodriguez-Lopez, Jhonny , Bernlohr, David , Knopf, Bailey A. , Lamming, Dudley W. , Johnston, Matthew J, Brown-Borg, Holly M., Tye, Spencer A, Rhoads, Timothy W. , Childs, Bennett G. , Li, Xinna, Jang, In Hwa, Camell, Christina D. , Miller, Zachary, Phatnani, Hemali , Haak, Andrew J. , Vanegas-Avendaño, Natalia, Akula, Ramya N, Limkar, Ajinkya R. , Leiser, Scott F, Correia, Jacinta , Bai, Hua, Olszewski, Szczepan, Seldeen, Kenneth L. , Budinger, G R Scott, Morales-Nebreda, Luisa C, Winter, Deborah R. , Spitzer, Shelly K McCrady, Rojas, Mauricio , Schafer, Marissa , Ashiqueali, Sarah A , Guthikonda, Prashanth, Rodriguez-Lopez, Jhonny , Monroe, T Blake , Bernlohr, David A , Lamming, Dudley W , Brown-Borg, Holly M , Rhoads, Timothy W , Gate, David M , Baker, Darren J , Li, Xinna , Miller, Zachary , Phatnani, Hemali , Konopka, Adam R , Limkar, Ajinkya R , Correia, Jacinta , Bai, Hua , Olszewski, Szczepan , Seldeen, Kenneth L , Morales-Nebreda, Luisa C , Winter, Deborah R , McCrady-Spitzer, Shelly K , Anderson, Rozalyn M , LeBrasseur, Nathan K , Schafer, Marissa J , Sturmlechner, Ines , Redden, James T., Passos, João F. , Robbins, Paul D. , Brown‐Borg, Holly M. , Tye, Spencer, Baker, Darren J. , Jang, In Hwa , Konopka, Adam R. , Ricke, William A. , Leiser, Scott F. , Morales‐Nebreda, Luisa , Anderson, Rozalyn M. , Mihaylova, Maria M. , Mora, Ana Lucia , LeBrasseur, Nathan K.

Mayo Clinic

The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences | December 23, 2025 | Volume: 81 | Issue: 3 | Pages: No page available

10.1093/gerona/glaf280 | PMID 41429578 Get It

Abstract Geroscience research benefits from interdisciplinary approaches, team science, and collaborations, which collectively facilitate the discovery of aging mechanisms and their translation into tangible, clinical interventions. Since its inception in 2019, the Midwest Aging Consortium (MAC) has provided an engaging platform for aging researchers in the United States’ Midwest to connect, collaborate, and exchange ideas. The Sixth Annual Research Symposium of the MAC held at the Mayo Clinic in Rochester, Minnesota, in April 2025 highlighted the continued impact of the MAC in bringing together aging researchers, including many trainees and early career investigators, into a collaborative environment. This record-setting event featured interdisciplinary research on key aging mechanisms, including lipid metabolism, mitochondrial dysfunction, stress response, cellular senescence, and immune adaptations across organ systems. New therapeutic concepts and clinical trial approaches were presented. Cutting-edge methodologies including single-cell and spatial transcriptomics, metabolomics, and organoid cultures, to dissect aging process in tissue-specific and systemic contexts also were presented. Overall, the MAC symposium underscored the translational potential of geroscience and reinforced the MAC’s mission to accelerate aging research through regional collaborations and innovation.
CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving 600 Mayo Clinic patients
Gangat, Naseema, Fathima, Saubia , Rokach, Lior , Ghosoun, Nour, Rezasoltani, Mahsa , Ilyas, Rimal, Alsugair, Ali, McCullough, Kristen , Abdelmagid, Maymona, Al‐Kali, Aref , Alkhateeb, H., Begna, Kebede H. , Mangaonkar, Abhishek, Matin, Aasiya, Hefazi, Mehrdad T., LITZOW, Mark R., Shah, Maleeha, Patnaik, Mrinal M. , Pardanani, Animesh, Foran, James M. , Palmer, Jeanne , Punwani, Nathan , Sproat, Lisa, Khera, Nandita , Tefferi, Ayalew, McCullough, Kristen B , Fathima, Saubia , Ghosoun, Nour, Ilyas, Rimal, Alkhateeb, Hassan B. , Mangaonkar, Abhishek A. , Matin, Aasiya , Saliba, Antoine N. , Hefazi, Mehrdad , Litzow, Mark R. , Hogan, William J , Shah, Mithun V , Pardanani, Animesh , Badar, Talha , Murthy, Hemant S. , Sproat, Lisa, Yi, Cecilia Arana , Tefferi, Ayalew , Gangat, Naseema

Mayo Clinic

No container title available | December 22, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-8233179/v1 Get It

Abstract The comparative value of liposomal cytarabine/daunorubicin (CPX-351) versus venetoclax plus a hypomethylating agent (Ven-HMA) in the frontline treatment of older adults with primary ( de novo ) or secondary acute myeloid leukemia (AML) remains uncertain. In the current study, we retrospectively examined outcomes of 600 patients with newly diagnosed AML treated with CPX-351 (N = 112) or Ven-HMA (N = 488). AML subtypes included de novo (46%), post-myelodysplastic syndrome (MDS) (19%), post-myeloproliferative neoplasm (MPN) (12%), post-MDS/MPN (6%), therapy-related (17%) and AML with myelodysplasia-related genetic abnormalities (AML-MR; 46%). Patients receiving CPX-351 were younger (median 65 vs. 73 years; p < 0.01), predominantly female (50% vs. 38%; p = 0.02), more likely to have secondary AML (68% vs. 51%; p < 0.01), and less likely to harbor NPM1 MUT (5% vs. 12%; p = 0.02). Rates of complete response with or without count recovery (CR/CRi) were comparable between CPX-351 and Ven-HMA (55% vs. 60%; p = 0.30), including in AML-MR (60% vs. 63%; p = 0.70). Ven-HMA use was associated with fewer infectious complications (62% vs. 83%; p < 0.01) and yielded higher CR/CRi rates in males (60% vs. 45%; p = 0.04), de novo AML (68% vs. 50%; p = 0.03), and in the presence of STAG2 MUT (86% vs. 44%; p = 0.02), or CEBPA MUT (88% vs. 50%; p = 0.03). Overall survival censored for transplant, was similar (median 10 vs. 13 months; p = 0.90), with Ven-HMA being superior in post-MDS AML (median 12 vs. 7 months; p = 0.02) and CPX-351 in the presence of SF3B1 MUT (not reached vs. 14 months; p < 0.01). Our findings suggest that Ven-HMA is as effective and less toxic than CPX-351 in newly diagnosed AML, including AML-MR, despite selection of younger, fitter patients for CPX-351.